A detailed history of Citigroup Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Citigroup Inc holds 74,205 shares of FATE stock, worth $123,180. This represents 0.0% of its overall portfolio holdings.

Number of Shares
74,205
Previous 47,869 55.02%
Holding current value
$123,180
Previous $157,000 64.97%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$3.12 - $5.57 $82,168 - $146,691
26,336 Added 55.02%
74,205 $259,000
Q2 2024

Aug 12, 2024

SELL
$3.26 - $7.08 $1.88 Million - $4.07 Million
-575,189 Reduced 92.32%
47,869 $157,000
Q1 2024

May 10, 2024

SELL
$3.54 - $8.35 $782,000 - $1.84 Million
-220,904 Reduced 26.17%
623,058 $4.57 Million
Q4 2023

Feb 09, 2024

BUY
$1.65 - $3.94 $1.38 Million - $3.29 Million
835,245 Added 9581.79%
843,962 $3.16 Million
Q3 2023

Nov 09, 2023

SELL
$2.02 - $5.04 $2.16 Million - $5.38 Million
-1,066,932 Reduced 99.19%
8,717 $18,000
Q2 2023

Aug 10, 2023

SELL
$4.76 - $6.59 $234,472 - $324,616
-49,259 Reduced 4.38%
1,075,649 $5.12 Million
Q1 2023

May 11, 2023

BUY
$4.24 - $11.12 $3.94 Million - $10.3 Million
929,215 Added 474.83%
1,124,908 $6.41 Million
Q4 2022

Feb 09, 2023

SELL
$9.86 - $23.83 $327,381 - $791,227
-33,203 Reduced 14.51%
195,693 $1.97 Million
Q3 2022

Nov 10, 2022

BUY
$21.04 - $36.06 $541,275 - $927,679
25,726 Added 12.66%
228,896 $5.13 Million
Q2 2022

Aug 10, 2022

BUY
$17.78 - $42.39 $3 Million - $7.16 Million
168,833 Added 491.69%
203,170 $5.04 Million
Q1 2022

May 12, 2022

SELL
$29.67 - $60.28 $2.15 Million - $4.36 Million
-72,341 Reduced 67.81%
34,337 $1.33 Million
Q4 2021

Feb 10, 2022

SELL
$47.84 - $64.34 $3.01 Million - $4.04 Million
-62,844 Reduced 37.07%
106,678 $6.24 Million
Q3 2021

Nov 10, 2021

BUY
$59.27 - $95.73 $10 Million - $16.2 Million
169,522 New
169,522 $10 Million

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $161M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.